Core Viewpoint - Huaxi Biological Technology Co., Ltd. (688363.SH) criticized certain brokerage reports for misleading the market regarding the comparison between hyaluronic acid and recombinant collagen, claiming these reports lack scientific basis and are intended to promote a competing product [1][3][6] Group 1: Company Response - Huaxi Biological reported that it has communicated with regulatory authorities regarding the misleading content in brokerage reports and received apologies from some institutions [1][4] - The company emphasized that the reports are part of a broader issue of "hasty capital" creating a false narrative in the market [3][4] - Huaxi Biological expressed disappointment that relevant parties are not engaging in scientific discussions but are instead focusing on social media commentary [4][5] Group 2: Brokerage Reports - The reports in question were authored by multiple brokerage firms, including Huatai Securities and others, which Huaxi Biological claims are biased towards a competitor, Juzhi Biological [3][6] - Analysts involved in the reports defended their work, stating that the content was compliant and based on objective public data, and denied any intent to promote Juzhi Biological [2][7][8] - The reports highlighted the advantages of recombinant collagen over hyaluronic acid in various applications, which Huaxi Biological disputes as lacking scientific evidence [3][6][8] Group 3: Market Context - In 2024, Juzhi Biological reported a revenue of 55.39 billion yuan, a 57.07% increase, surpassing Huaxi Biological's revenue of 53.71 billion yuan, which declined by 11.61% [6] - Juzhi Biological's core brand, Kefu Mei, contributed 82% of its revenue, showcasing the competitive landscape in the beauty and medical aesthetics industry [6]

玻尿酸巨头华熙生物近期向券商"开炮"，揭开了医美行业"热点轮动"的一角！ 针对突然向券商"开炮"，周二华熙生物对每经作出最新回应，华熙生物表示，透明质酸产业一直希望其 作为行业龙头带头发声，纠正对透明质酸的罔顾科学的踩踏和抹黑。此次发声是基于多重考虑，且已和 两大行业协会沟通并获得支持。 这一回应针对华熙生物5月17日在微信公众号发布的长文，其在文中驳斥了"玻尿酸过时"的观点，并点名 了多家券商炒作"重组胶原蛋白"，与玻尿酸进行恶意对比。 "炮轰"的背后隐藏着华熙生物的困境，随着玻尿酸产能过剩价格不断下降，行业竞争也在不断加剧，华 熙生物的业绩已经开始失速，2024年扣非净利缩水78.13%，市值也较巅峰缩水超1000亿。 反观，重组胶原蛋白成为市场的"新宠"，行业中巨子生物司股价一路走高，其业绩上完成了对华熙生物 的反超，2024年归母净利润仅为巨子生物净利润的十二分之一左右。 华熙生物发长文"开撕"券商 华熙生物认为，透明质酸"过时论"的兴起，本质上是一场由"浮躁资本"构建的题材幻象，试图用"神话过 时"绕开中国产业发展必然面临的进阶过程，引导资本和市场资源聚焦于资本新题材，用"新贵登场"塑造 沙土高楼。 ...

Core Viewpoint - The article discusses the ongoing debate in the capital market regarding the valuation and relevance of hyaluronic acid, with Huaxi Biological refuting claims that it is outdated, labeling such views as a product of "restless capital" [1][3][9]. Group 1: Company Positioning - Huaxi Biological published an article on May 17, 2023, directly criticizing nine brokerage reports that suggested hyaluronic acid is outdated, asserting that this narrative is misleading and harmful to the industry [1][3]. - The company emphasized the importance of voicing its stance to protect the integrity of the hyaluronic acid industry, which has been developed over decades of scientific research [6][9]. - Huaxi Biological's market share in the global hyaluronic acid market was reported at 44% in 2021, with China accounting for 82% of global sales [6]. Group 2: Market Dynamics - The article highlights a shift in capital market interest from hyaluronic acid to recombinant collagen, with companies like Juzhibio gaining significant market traction [10][15]. - Juzhibio's stock price has surged nearly 70% in 2023, positioning it as a leading player in the beauty and skincare sector, while Huaxi Biological and other hyaluronic acid companies have seen declining performance [10][13]. - The market for recombinant collagen is projected to grow at a compound annual growth rate (CAGR) of 44.93%, reaching 585.7 billion yuan by 2025 [16]. Group 3: Industry Trends - The article notes that the beauty and skincare industry is experiencing rapid shifts, with companies needing to adapt to changing consumer preferences and capital market trends [2][15]. - Huaxi Biological has begun to diversify its product offerings, launching multiple collagen products and obtaining medical device registrations to stay competitive [17]. - The competitive landscape for recombinant collagen is intensifying, with various companies entering the market, indicating that maintaining a leading position will be challenging for Juzhibio [16][17].

Group 1 - The article discusses the challenges faced by the hyaluronic acid (HA) industry, claiming it has been misrepresented and undermined in recent years due to misleading narratives in the capital market [2][6] - Huaxi Biological specifically names several securities firms and their reports that have contributed to the negative perception of HA, including Huatai Securities and Anxin Securities [2][5][7] - The company argues that the rise of the "outdated" narrative surrounding HA is a result of a capital market phenomenon that seeks to shift focus to new investment themes, thereby undermining established industries [6][8] Group 2 - Huaxi Biological highlights the significant growth of competitor Juzhi Biological, which reported a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.07%, and a net profit of 2.062 billion yuan, up 42.06% [5][10] - The company emphasizes its own historical performance, noting that from 2018 to 2022, it experienced substantial revenue and profit growth, with annual revenue growth rates exceeding 87% and net profit growth rates surpassing 90% [10] - However, Huaxi Biological has faced a sharp decline in performance recently, with a projected revenue of 5.371 billion yuan and a net profit of 174 million yuan in 2024, representing year-on-year decreases of 11.61% and 70.59% respectively [10][11] Group 3 - The company is undergoing significant internal reforms, described as a "bone-scraping" process, initiated by the chairman to address management issues and improve operational efficiency [10][11] - The article indicates that Huaxi Biological is currently facing both internal challenges due to its restructuring efforts and external pressures from competition in the market [11]

Core Viewpoint - The news highlights the rise of Fan Daidi, the new vice president of Northwest University, as a prominent figure in the business world, particularly in the biotechnology sector, due to her significant stake in the listed company, Juzhi Biotechnology, which has achieved substantial market value and success in the industry [1][4]. Company Overview - Juzhi Biotechnology, co-founded by Fan Daidi and her husband Yan Jianya in 2001, has successfully commercialized human-like collagen through genetic engineering, becoming a model for industry-academia collaboration [3]. - As of 2017, Juzhi Biotechnology had established 11 production lines, with its products being used in over 1,000 hospitals across seven countries and regions, achieving cumulative terminal sales of nearly 10 billion yuan [3]. Market Performance - Juzhi Biotechnology went public on the Hong Kong Stock Exchange in November 2022, with Fan Daidi listed as a co-founder and chief scientific officer [3]. - As of May 12, 2023, Juzhi Biotechnology's market capitalization was approximately 836 billion HKD (about 773 billion yuan), contributing significantly to the combined market value of nearly 900 billion yuan for both Juzhi Biotechnology and another listed company, Xi'an Triangle Defense [4]. Leadership and Governance - Fan Daidi was appointed as the vice president of Northwest University on April 1, 2025, after serving in various leadership roles within the university [4]. - The appointment of Fan Daidi complies with the management regulations for leadership personnel in public institutions in Shaanxi Province, confirming her eligibility for the role [4].

5月20日，港股消费板块早盘震荡攀升，相关热门ETF中，港股消费ETF（513230）现涨近1.5%。持仓股中，零跑汽车领涨超4%，小米集团、新秀丽均 跟涨超3%，巨子生物、思摩尔国际、阿里巴巴等涨幅居前。港股消费ETF（513230）近期回暖趋势较为清晰，已连续3个交易日获资金净流入，持续受资金 青睐。 消息面上，2025年全国精品首发季暨"首发上海"系列活动日前正式在上海启动，邀请全球游客打卡首店、观赏首展、欣赏首秀，实地感受中国和上海消 费市场的巨大魅力。上海还同步发布了"首发上海3.0"政策，将试点首发进口消费品检验便利化措施和首发进口化妆品快速通关模式，进一步优化全球新品 的首发环境。据悉，商务部将组织各地开展丰富多彩、各具特色的精品首发活动，激发消费新动能，持续释放消费潜力。同时，将加大对首发经济的支持力 度，发挥好重点展会作用。 开源证券认为， 消费复苏主旋律下，关注契合"情绪消费"主题且品牌势能和竞争力边际提升的龙头公司，重点关注四条投资主线。（1）黄金珠宝：关 注具备差异化产品力和消费者深度洞察力的黄金珠宝品牌；（2）线下零售：关注顺应趋势积极变革探索的零售企业（超市、百货、连锁）；（3）化 ...

Group 1: Personal Care Industry - The personal care sector is experiencing growth driven by increased national income and health demands, providing opportunities for domestic brands to gain market share [1] - Douyin's channel is accelerating the online growth of personal care products, with GMV growth expected to reach 38.86% in 2024, significantly outpacing cosmetics [1] - Recommended stocks include companies with clear technological advantages and strong operational capabilities, such as Dengkang Oral Care and Runben Co., with a focus on brands that combine technological innovation and channel control [1] Group 2: Cosmetics Industry - The cosmetics industry saw an unexpected growth rate of 3.2% in Q1 2025, attributed to consumption promotion policies and a low base effect, entering a phase of normalized growth [2] - Foreign brands are facing dual pressures from tariffs and store closures, leading to a negative performance, while domestic brands are actively innovating and expanding their product lines [2] - Recommended stocks include Marubi and Proya, with a focus on companies that are actively innovating and showing strong performance [2] Group 3: Offline Beauty Care - The offline beauty care sector is experiencing a divided performance, driven by supply-side innovations, particularly in new materials like collagen and hydroxyapatite [3] - Companies like Jinbo Bio are leading in the field of recombinant collagen, with a rich product layout and capacity expansion plans [3] - The offline beauty care industry is expected to benefit from technological innovations and supportive consumption policies, with recommendations for Jinbo Bio and Juzhi Bio [3]

截至2025年5月20日 09:35，恒生医疗保健指数(HSHCI)强势上涨2.69%，成分股三生制药(01530)上涨33.93%，欧康维视生物-B(01477)上涨7.44%，再鼎医药 (09688)上涨6.39%，石药集团(01093)，诺诚健华(09969)等个股跟涨。恒生医疗ETF(513060)高开高走上涨2.48%，冲击3连涨。最新价报0.50元。流动性方 面，恒生医疗ETF盘中换手2.6%，成交2.66亿元。拉长时间看，截至5月19日，恒生医疗ETF近1月日均成交12.37亿元，居可比基金第一。 湘财证券指出，近期在国家鼓励创新大背景下创新药产业链表现活跃，虽然医药工业复苏仍有待验证，行业受医保控费压力仍在，但多层次的支付体系正在 建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向，具体而言：（1）高成长：医药外包服务中的ADCCDMO、减肥药 产业链多肽CDMO等方向公司。（2）预期改善：盈利能力有望触底回升的第三方检验医学实验室，消费医疗中的眼科及口腔等方向的公司。 恒生医疗ETF紧密跟踪恒生医疗保健指数，恒生医疗保健指数提供一项市场参考指标，反映在香港上市、主要 ...

2025 年 05 月 20 日 开源晨会 0520 ——晨会纪要 数据来源：聚源 -32% -16% 0% 16% 32% 48% 2024-05 2024-09 2025-01 沪深300 创业板指 昨日涨跌幅前五行业 | 行业名称 | 涨跌幅(%) | | --- | --- | | 综合 | 1.987 | | 环保 | 1.873 | | 房地产 | 1.751 | | 国防军工 | 1.051 | | 社会服务 | 1.024 | | 数据来源：聚源 | | 沪深300 及创业板指数近1年走势 吴梦迪（分析师） wumengdi@kysec.cn 证书编号：S0790521070001 观点精粹 【地产建筑】新房上海同环比领涨，一线新房价格环比持平——行业点评报告 -20250519 【地产建筑】销售面积降幅持续收窄，国内贷款增速转正——行业点评报告 -20250519 【机械】特斯拉机器人"丝滑"起舞，智能化大幅提升，硬件趋向定型——行业 周报-20250518 【建材】城市更新行动进度加速，关注建材投资机会——行业周报-20250518 【传媒】多模态 AI 继续迭代，IP 产业资本化或加快— ...

Investment Rating - The report does not explicitly state an overall investment rating for the industry, but it provides various recommendations across different sectors [6][44]. Core Insights - In April, the total retail sales of consumer goods reached 37,174 billion yuan, with a year-on-year growth of 5.1%. Excluding automobiles, retail sales amounted to 33,548 billion yuan, growing by 5.6% year-on-year [3][6]. - The retail sector shows stable growth, with online sales accelerating. The food and beverage sector is experiencing a rebound, while the hotel industry continues to face pressure. The automotive sector is seeing expanded discounts, and there are recommendations for companies in the automotive and robotics sectors [6][11][18]. - The report emphasizes the importance of new consumption opportunities, particularly in home furnishings, and notes that the household appliance sector is benefiting from national subsidies [6][24][33]. Summary by Category Retail - Retail sales in April showed a steady growth, with online sales accelerating. Offline sales remained stable, with significant growth in convenience stores and specialty shops [11][12]. - Essential goods like food and daily necessities saw strong growth, while cosmetics and jewelry also performed well due to low base effects and e-commerce growth [12][13]. Food and Beverage - The food and beverage sector is undergoing optimization and adjustment, with signs of recovery. Retail sales of food products increased by 14.0% year-on-year in April [29][31]. - The alcoholic beverage sector is stabilizing, with a focus on high-end products and a gradual recovery in demand [30][31]. Automotive - The automotive sector reported a total retail sales of 362.6 billion yuan in April, with a year-on-year increase of 0.7%. The penetration rate of new energy vehicles remains high, with significant growth in sales [18][19]. - The report highlights the ongoing price war among car manufacturers, which may stimulate short-term sales but could pressure industry margins in the long run [19][20]. Apparel and Textiles - Retail sales in the apparel sector showed a slowdown, with a recommendation to focus on domestic demand and potential growth opportunities [22]. - The report suggests that brands with strong market positions and innovative products are likely to perform better in the current environment [22]. Household Appliances - The household appliance sector is experiencing accelerated growth, supported by national subsidies. Retail sales in April increased by 38.8% year-on-year [33][34]. - The report notes a positive trend in both online and offline sales across various appliance categories, indicating strong consumer demand [34][35]. Personal Care - The personal care sector continues to show steady growth, with a year-on-year increase of 7.6% in retail sales. The report recommends focusing on brands in oral care and women's care segments [25]. Light Industry - The light industry is encouraged to focus on new consumption opportunities, particularly in home furnishings, which are benefiting from government support [24]. Jewelry - The jewelry sector is highlighted for its strong performance, with significant year-on-year growth driven by rising gold prices and consumer demand for investment-type products [12][13]. Cross-Border Trade - The report emphasizes the trend of high-quality Chinese brands and manufacturing expanding into global markets, suggesting a favorable outlook for companies with strong resources and brand strength [13].